Evaluating Procedural Factors of Drug-Coated Balloon Treatment in Coronary Artery Disease during PCI
A Multicenter, Prospective, Observational Registry
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2026-08-28
500
Participants Needed
7
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how procedural factors of drug-coated balloon DCB treatment affect patients with de novo coronary lesions undergoing percutaneous coronary intervention PCI. This observational registry focuses on delivery time from Y-to-B and inflation duration to understand their influence on angiographic and clinical outcomes. The goal is to analyze these impacts to potentially develop new techniques and pretreatment strategies to improve DCB treatment.
Participants receive DCB treatment as part of their PCI procedure for new coronary artery lesions. The study observes the timing and duration aspects of the procedure without altering standard care. There is one main group of patients undergoing this DCB treatment strategy, and the study collects data during their routine PCI procedures.
During the study, participants will be monitored for angiographic outcomes, including the occurrence of target lesion restenosis, and clinical outcomes such as target vessel failure, assessed between 6 to 12 months after treatment. The research team collects relevant clinical data and follows participants for up to approximately two years, ensuring safety and comprehensive outcome measurement throughout the study period.
CONDITIONS
Brief Title
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease
Research Team
F
Fei Ye, MD
T
Tian-lei Zhang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Nanjing First Hospital, Nanjing Medical University
Lead Sponsor
Who Can Participate
Age: 18Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
Diagnosis of stable coronary artery disease or unstable angina
Presence of a new coronary lesion with reference vessel diameter between 2.25 and 4.0 mm and lesion length up to 40 mm
Planned treatment strategy using drug-coated balloon for PCI
Provided written informed consent
You will not qualify if you...
Acute myocardial infarction within the past 72 hours
Severe heart failure classified as NYHA class IV
Severe liver or kidney dysfunction
Allergy to drug-coated balloon components or antiplatelet drugs, or intolerance to dual antiplatelet therapy
Life expectancy less than 12 months
Pregnancy or breastfeeding
Participation in another clinical trial at the same time
Presence of in-stent restenosis
Unsuccessful reopening of main vessel or side branch chronic total occlusion
Hemodynamic instability
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Observation
Duration - During PCI procedure
Participants undergo their planned drug-coated balloon treatment for new coronary lesions, during which procedural factors like delivery time and inflation duration are recorded and monitored.
Single procedure visit
Follow-up
Duration - 6 to 12 months
Participants are followed for clinical and angiographic outcomes, including restenosis and vessel failure, assessed between 6 to 12 months after treatment.
Follow-up visits during this period
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Study of Implantable Cardioverter Defibrillator Benefits in Adults with Coronary Artery Disease and Ventricular Fibrillation After Complete Revascularization
Randomized Double-Blind Study Evaluating Intravenous YN001 Versus Placebo in Adults With Coronary Atherosclerosis Receiving Cardiovascular Risk Therapy
Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure
Real-World Registry of Quantitative Flow Ratio-Guided Coronary Revascularization and Quality Evaluation Across Multiple Centers in China
Evaluating Coronary CT Angiography to Guide Calcium Modification Compared to Intravascular Ultrasound in Treating Calcified Coronary Artery Disease A Multicenter Randomized Trial
Study on Ultrasound Screening and Combined Treatments for Patients With Coronary and Head and Neck Artery Narrowing
Study of Yiyang Huoluo Decoction Combined with Western Medicine to Treat Coronary Heart Disease and Atherosclerosis in Older Adults
Evaluating Pre-Procedural Intracoronary Nicorandil to Prevent Reduced TIMI Flow in Patients Undergoing Percutaneous Coronary Intervention for Coronary Artery Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Comparison of Limus and Paclitaxel Drug-Coated Balloons, Second-Generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials.
Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.